Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026

Reports
Published
Number of pages
1500

For Wire/Bank transfer, contact us at info@pnspharma.com

Electronic Access - Single User License
$3000
CD-ROM Mail Delivery
$4200
Hard Copy Mail Delivery
$5100
Electronic Access - Multi-User License
$6000

"Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlight:

  • Global Gene Therapy Market Opportunity: > US$ 8 Billion
  • Global Gene Therapy Clinical Pipeline:  > 1000 Therapies In Clinical Trials
  • Commercially Available Gene Therapies: 11
  • USA Dominates Global Gene Therapy Pipeline: > 500 Therapies In Clinical Trials
  • Cancer Accounts For 50% of Global Gene Therapy Trials

 

The potential of gene therapy approach to address the diseases that are unable to get treated with any other treatment is quickly becoming a reality and the approval of gene therapy products for the commercial use is seeking for a fascinating breakthrough over the other achievements that mankind has achieved over the decades. Gene therapy brings with it the promise of one-time treatment of the target that are underlying the genetic level. The therapy has brought several fascinating companies that are currently conducting research about the trending area of biotech. Gene therapy tends to bring an increase in the baby boomer generation compelled to grow and live longer.   

The research report “Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026” is poised towards the current market trends followed by the therapy since its advent at international level and delivering a summarized information about the whole concept of the gene therapy in order to restore the gene functions by manipulating the genetic code present within the genome. The report discusses the current available gene therapy agents with their complete data regarding the dosage, sales and pricing  compiled from multiple sources and from publications by companies that are thriving the market of gene therapy. The entire clinical and non-clinical framework along with the countries encompassed with the presence of agents is also discussed. The report highlights the need of such advanced technique and the entire huge breakthrough the technique is going through.         

 

The whole arena of gene therapy came into limelight when the therapy treated the first patient having ADA-SCID. Since then, the fundamental benefits received from the therapy never got limited. The therapy has blessed the patients many agents with unique strategies and nonetheless many efforts made by the researchers are underway to get utilized against the diseases that have no other viable treatment. The therapy can alter the target DNA sequence by silencing, replacing or by manipulating the level of the substitute protein in order to restore the patient’s body against the target disease.

 

As there are various diseases that are associated with cancer, therefore the technology provides a potential treatment for the patient and it is expected that the therapy will provide deep insight about the genetic diseases and its treatment in future too. For the future, the gene therapy process is believed to be at a crucial position and will undoubtedly revolutionize the clinical, preclinical and technical techniques utilized in the laboratories. The editing of specific genes present in the pool of genome is considered as a groundbreaking discovery like the discovery of vaccines and antibiotics. It is just the matter of time that the technology will be categorized as a  dominating one over the other available technologies.

 

 

Gene therapy has been designed such that it can provide relief to the patients with rare genetic disease with one approach i.e. manipulation at the genetic level. One approach of the technique gets investigated for a number of results which in-turn results in the approval of several gene therapy agents in a regulated way.  In exchange, the therapy also entails for a cheap and one-time treatment- single injection or infusion when compared with the many years of expensive ongoing treatment.

 

The advent of the therapy for the well-being of the patients has definitely shifted the timings of the healthcare costs. The novel gene therapy agents anticipation in the market has successfully determined the value of the gene therapy and its urgency. The value based research of the therapy has gained the interest of the clinicians and researchers ensuring the best of the benefits from the therapy. The comparative effectiveness and cost-effectiveness have inclined the dependency of the patients towards gene therapy while gaining excess commercial success in the global market.  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1.  Introduction to Gene Therapy

 

  1.1     Gene Therapy: An Overview

  1.2     History of Development

 

2. Gene Therapy & its Impact on Genetic Alterations

 

  2.1     Gene Therapy as a Mastermind of Genetic Revolution

  2.2     Manipulations at Molecular Level by Gene Therapy

 

3. Working Mechanism of Gene Therapy

 

  3.1     Classification of Gene Therapy on the Basis of Cell Type

    3.1.1 Somatic Gene Therapy

    3.1.2 Germline Gene Therapy

 

  3.2 Classification on the Basis of Gene Delivery Mechanism

    3.2.1 Ex-Vivo Delivery of the Gene

    3.2.2 In-Vivo Delivery of the Gene

 

  3.3 Classification on the Basis of Gene Delivery Methods

    3.3.1 Viral Methods

    3.3.2 Non-Viral Methods

 

  3.4 Classification on the Basis of End-Results

    3.4.1 Augmentation Gene Therapy

    3.4.2 Targeted Gene Therapy

 

 

4. Molecular Tools Available for Gene Therapy

 

  4.1     Targeting Specific Loci with ZFN’s

  4.2     Introduction of TALEN’s as a Gene Therapy Tool

  4.3     Development of CRISPR to Mediate Precise Genome Editing

 

5. Strategies Opted by Gene Therapy

 

  5.1     Replacement of Defective Genes with Healthy Genes

  5.2     Fixing Mutated Genes by Gene Therapy Molecular Tools

  5.3     Gene Therapy Modifying the Diseased Cells & Making them Evident against Immune Cells

 

6. Gene Therapy & the Journey of Clinical Trials Associated

 

  6.1     Trends Associated with Clinical Research & Trials

 

    6.1.1 Clinical Trials Regarding Gene Therapy: Disease Analysis

    6.1.2 Clinical Trials Regarding Gene Therapy: Vector Analysis

    6.1.3 Clinical Studies Regarding Gene Therapy: Global Analysis

    6.1.4 Clinical Trials Regarding Gene Therapy: Gene Type Analysis

    6.1.5 Clinical Trials Regarding Gene Therapy: Current Status

    6.1.6 Clinical Trials Regarding Gene Therapy: Gender Analysis

    6.1.7 Clinical Trials Regarding Gene Therapy: Funding Analysis

 

7. Approach of Gene Therapy Against Cancer

 

  7.1     Clinical Efficacy of Gene Therapy for Cancer Cells

  7.2     Gendicine®: A Wide Spectrum Anti-Cancer Gene Therapy Agent

  7.3     Rexin-G® for Osteosarcoma & Soft Tissue Sarcoma

  7.4     Kymriah®: A Breakthrough Gene Therapy Product for B-Cell Acute Lymphoblastic Leukemia

  7.5     Yescarta®: Gene Therapeutic Approach for B-Cell Lymphoma

  7.6     Oncorine® Approval by Shanghai Sunway Biotech Co. Ltd.

  7.7     Gene Therapy Product Imlygic® against Melanoma

 

8. Gene Therapy for the Treatment of Neuromuscular Diseases - Spinal Muscular Atrophy & Duchenne Muscular Dystrophy

 

  8.1     Clinical Approach of Gene Therapy for Duchenne Muscular Dystrophy

  8.2     Clinical Approach of Gene Therapy for Spinal Muscular Atrophy

  8.3     Spinraza® - First Approved Gene Therapy Product for Spinal Muscular Atrophy

  8.4     Zolgensma® Treatment for Spinal Muscular Atrophy Patients

  8.5     Eteplirsen – A New Hope for the Patients with Duchenne Muscular Dystrophy

 

9. First Targeted Treatment for Rare Inherited Retinal Dystrophy

 

  9.1     Clinical Efficacy of the Gene Therapy Products

  9.2     Luxturna® for the Treatment of RPE65 Mutation Associated Retinal Dystrophy

 

10. Gene Therapy Mediated Treatment of Peripheral Artery Disease

 

  10.1   Clinical Interference for Cardiovascular Disorders Gene Therapy

  10.2   Neovasculgen® Gene Therapy in Cardiovascular Diseases

 

11. Correcting Severe Combined Immunodeficiency – Adenosine Deaminase Deficiency through Gene Therapy

 

  11.1   Clinical Potential of Gene Therapy Therapeutic Approach

  11.2   Strimvelis® Benefits for Rare Disease: Adenosine Deaminase Deficiency– Severe Combined Immunodeficiency

 

12. Success of Gene Therapy over Other Diseases

 

13. Availability & Revolution of Gene Therapy Drugs in the Market

 

 

14. Gene Therapy Products Dosage & Price Analysis

 

  14.1   Kymriah®

  14.2   Yescarta®

  14.3   Spinraza®

  14.4   Zolgensma®

  14.5   Luxturna

  14.6   Strimvelis

  14.7   Eteplirsen

  14.8   Imlygic

 

15. Global Gene Therapy Clinical Trials Insight

 

  15.1   By Phase

  15.2   By Country

  15.3   By Formulation

  15.4   By  Company

  15.5   By Target

  15.6   By Indication

 

16. Global Gene Therapy Clinical Trials By Company, Indication & Phase

 

  16.1   Research

  16.2   Preclinical

  16.3   Clinical

  16.4   Phase-0

  16.5   Phase-I

  16.6   Phase-I/II

  16.7   Phase-II

  16.8   Phase-II/III

  16.9   Phase-III

  16.10 Preregistration

  16.11 Registered

 

17. Marketed Gene Therapy Clinical Insight

 

  17.1   YESCARTA

  17.2   Kymriah

  17.3   ZOLGENSMA

  17.4   Gendicine

  17.5   IMLYGIC

  17.6   Glybera

  17.7   INVOSSA

  17.8   LUXTURNA

  17.9   Neovasculgen

  17.10 Zalmoxis

  17.11 Rexin-G

 

18. Global Market Landscape of Gene Therapy

 

  18.1   Gene Therapy Market Overview

  18.2   Gene Therapy Market - Regional Analysis

 

    18.2.1 US

    18.2.2 Europe

    18.2.3 Japan

    18.2.4 China

    18.2.5 India

    18.2.6 South Korea

    18.2.7 Taiwan

 

19. Mergers & Collaborations between Major Key Players of the Market

 

  19.1   Axovant Gene Therapies & Yposkesi’s Strategic Partnership

  19.2   Lonza and DiNAQOR AG’s Strategic Collaboration

  19.3   US$ 1 Million to AavantiBio for Gene Therapy Development in Freidreich’s Ataxia

  19.4   Actinium Pharmaceuticals Collaboration with UC Davis for HIV-Related Lymphoma for ACT Gene Therapy Program

 

20. Global Gene Therapy Market Dynamics

 

  20.1   Factors Driving the Growth of Gene Therapy

 

    20.1.1 Gene Therapy Dominant over Growing Prevalence of Cancer

    20.1.2 Increased R&D Activities with Rising Investments

    20.1.3 Increasing General Awareness Concerning Gene Therapy

 

  20.2   Challenges Overpowering the Technology

  20.3   Future Opportunities for Gene Therapy

 

21. Competitive Landscape

 

  21.1   Novartis

  21.2   Spark Therapeutics

  21.3   BioGen

  21.4   Sarepta Therapeutics

  21.5   Kite Pharma

  21.6   Amgen

  21.7   Solid Biosciences Inc.

  21.8   uniQure NV

  21.9   MeiraGTX Holdings

  21.10 Audentis Therapeutics

  21.11 Regenxbio Inc.

  21.12 Alnylam Pharmaceuticals

  21.13 Arrowhead

  21.14 SQZ Biotechnologies

  21.15 Bluerock Therapeutics

  21.16 Zydus Takeda

  21.17 Intrexon Corporation

  21.18 Celgene

  21.19 Roche

  21.20 Oxford Biomedica

  21.21 Genethon

  21.22 Sangamo Biosciences

  21.23 Juno Therapeutics

  21.24 Cellectis

  21.25 Autolus Therapeutics plc

  21.26 icell Gene Therapeutics

  21.27 Allogene Therapeutics

Figure 1-1: Basic Gene Therapy Technique

Figure 1-2: Milestones in Gene-Based Therapies

 

Figure 2-1: Molecular Requirements for Conducting Gene Therapy

Figure 2-2: Number of Protocols Approved for Gene Therapy, 1999 & 2015

Figure 2-3: Global - Percentage of Gene Therapy Protocols at Different Phases

 

Figure 3-1: General Procedure for Performing Gene Therapy

Figure 3-2: Classification of Gene Therapy on the Basis of Working

Figure 3-3: Differentiation of Gene Therapy on the Basis of Cell Type

Figure 3-4: General Mechanism of Somatic Gene Therapy

Figure 3-5: Areas of Somatic Gene Therapy Utilization

Figure 3-6: Success Percentage of Somatic Gene Therapy in Different Diseases

Figure 3-7: General Mechanism of Germline Gene Therapy

Figure 3-8:  Differentiation of Gene Therapy on the Basis of Gene Delivery Mechanisms

Figure 3-9: Ex-Vivo Delivery Mechanism for Gene Therapy

Figure 3-10: Methods for In-Vivo Delivery of the Gene Therapy

Figure 3-11: Differentiation of Gene Therapy on the Basis of Gene Delivery Methods

Figure 3-12: Viral Vectors for Gene Therapy

Figure 3-13: General Mechanism of Virus Vectors for Gene Therapy

Figure 3-14: Non-Viral Methods of Gene Delivery

Figure 3-15: Ultrasound Irradiation Leading to Membrane Pores

Figure 3-16: Types of Gene Therapy on the Basis of End-Results

Figure 3-17: Strategies Opted by Targeted Gene Therapy

 

Figure 4-1: Molecular Tools Available for Performing Gene Therapy

Figure 4-2: CompoZr ® - Price of a Single Kit (US$), January’ 2019

Figure 4-3: Domains of TALE & their Respective Functions

Figure 4-4: Applications of CRISPR-Cas9 Gene Editing Technology

 

Figure 5-1: Overall Strategy for Gene Alteration Played by Gene Therapy

Figure 5-2: Gene Replacement Therapy

Figure 5-3: Gene Therapy Molecular Tool Participation in Fixing Defective Genes

Figure 5-4: Modification of Immune Cells with Gene Therapy

 

Figure 6-1: Global - Gene Therapy Clinical Trials by Diseases (%), 2019

Figure 6-2: Global - Number of Gene Therapy Clinical Trials by Diseases, 2020

Figure 6-3: Global - Clinical Trials on Monogenic Diseases (%), 2004, 2007, 2012 & 2017

Figure 6-4: Global - Vectors Used in Clinical Trials (%), 1989 - 2017

Figure 6-5: Global - Number of Gene Therapy Clinical Trials Approved, 2010 - 2018

Figure 6-6: Global - Types of Genes Transferred in Gene Therapy Clinical Trials (%), 2017

Figure 6-7: Global - Number of Different Types of Genes Transferred in Gene Therapy Clinical Trials, 2017

Figure 6-8: Global - Number of Gene Therapy Trials in Different Phases, January’ 2020

Figure 6-9: Global - Number of the Gene Therapy Clinical Trials in Different Status, January’2020

Figure 6-10: Global – Status of Gene Therapy Clinical Trials (%), January’2020

Figure 6-11 : Global - Total Number of Active, Not Recruiting Gene Therapy Clinical Trials, January’ 2020

Figure 6-12: Global - Active, Not Recruiting Gene Therapy Clinical Trials (%), January’ 2020

Figure 6-13: Global - Total Number of Completed Gene Therapy Clinical Trials, January’ 2020

Figure 6-14: Global - Completed Gene Therapy Clinical Trials (%), January’ 2020

Figure 6-15: Global - Total Number of Terminated Gene Therapy Clinical Trials, January’ 2020

Figure 6-16: Global - Terminated Gene Therapy Clinical Trials (%), January’ 2020

Figure 6-17: Global - Total Number of Withdrawn Gene Therapy Clinical Trials, January’ 2020

Figure 6-18: Global - Withdrawn Gene Therapy Clinical Trials (%), January’ 2020

Figure 6-19: Global - Number of Clinical Trials with Male Participants, January’2020

Figure 6-20: Global - Clinical Trials with Male Participants (%), January’2020

Figure 6-21: Global - Number of Clinical Trials with Female Participants, January’2020

Figure 6-22: Global - Clinical Trials with Female Participants (%), January’2020

Figure 6-23: Global - Gene Therapy Clinical Trials Funding Status, January’2020

Figure 6-24: Global - Gene Therapy Clinical Trials Funding Status (%), January’2020

 

 

Figure 7-1: Oncolytic Viruses Used in Gene Therapy Clinical Trials for Cancer

Figure 7-2: In-Vivo & Ex-Vivo Approved Drugs for Cancer Gene Therapy

Figure 7-3: Strategies Adapted by Gene Therapy Products against Cancer Cells

Figure 7-4: Global - Kymriah® - Clinical Trials Start & Estimated Completion Year, January’ 2020

Figure 7-5: Global - Yescarta® - Clinical Trials Start & Estimated Completion Year, January’ 2020

Figure 7-6: Global - Imlygic® - Active Clinical Trials Start & Estimated Completion Year, January’ 2020

 

Figure 8-1: Global – Population of Children below 14 Years (%), 2018

Figure 8-2: Global - Cases of Spinal Muscular Atrophy Type I before Birth (%), 2017

Figure 8-3: Global - Cases of Spinal Muscular Atrophy Type III (%), January’ 2020

Figure 8-4: Patients with Homozygous Deletion of SMN1 Gene (%), 2017

Figure 8-5: Global - Origin of Spinal Muscular Atrophy Patients (%), 2017

Figure 8-6: Global – Number of Patients of Spinal Muscular Atrophy from Different Origins, 2017

Figure 8-7: Europe – Distribution of Spinal Muscular Atrophy Patients (%), 2017

Figure 8-8: Europe – Distribution of Spinal Muscular Atrophy Patients, 2017

Figure 8-9: Europe – Spinal Muscular Atrophy Patient Population (%), 2017

Figure 8-10: Europe – Number of Spinal Muscular Atrophy Patients, 2017

Figure 8-11: Global – Distribution of Patients with Spinal Muscular Atrophy Subtypes (%), 2017

Figure 8-12: Global – Spinal Muscular Atrophy Patients by Gender (%), 2017

Figure 8-13: Global – Number of Spinal Muscular Atrophy Patients by Gender, 2017

Figure 8-14: Global – Distribution of Spinal Muscular Atrophy Patients by Age Group (%), 2017

Figure 8-15: Global – Number of Spinal Muscular Atrophy Patients by Age Group, 2017

Figure 8-16: Age of Development of Clinical Signs for Duchenne Muscular Dystrophy, 2020

Figure 8-17: Mutations Leading to the Development of Duchenne Muscular Dystrophy (%), 2019

Figure 8-18: Strategies by Gene Therapy for Duchenne Muscular Dystrophy

Figure 8-19: Global - Conducted Gene Therapy Clinical Trials for Duchenne Muscular Dystrophy, January’ 2020

Figure 8-20: Gene Therapy Strategies for Spinal Muscular Atrophy

Figure 8-21: Global – Spinal Muscular Atrophy - Clinical Trials Start & Estimated Completion Year, January’ 2020

Figure 8-22: Global - Spinraza® – Active        Clinical Trials for Spinal Muscular Atrophy Start & Estimated Completion Year, January’ 2020

Figure 8-23: Global - Spinraza® – Recruiting Clinical Trials for Spinal Muscular Atrophy Start & Estimated Completion Year, January’ 2020

Figure 8-24: Global - Spinraza® – Recruiting Clinical Trials for Spinal Muscular Atrophy II Start & Estimated Completion Year, January’ 2020

Figure 8-25: Global - Spinraza® – Recruiting Clinical Trial for Spinal Muscular Atrophy III Start & Estimated Completion Year, January’ 2020

Figure 8-26: Global - Zolgensma® - Active     Clinical Trials for Spinal Muscular Atrophy Start & Estimated Completion Year, January’ 2020

Figure 8-27: Global - Zolgensma® - Recruiting Clinical Trial for Spinal Muscular Atrophy Start & Estimated Completion Year, January’ 2020

Figure 8-28: Global - Zolgensma® - Recruiting Clinical Trial for Spinal Muscular Atrophy I Start & Estimated Completion Year, January’ 2020

Figure 8-29: Global - Eteplirsen – Active Clinical Trial Starting & Estimated Completion Year for Duchenne Muscular Dystrophy, January’ 2020

Figure 8-30: Global - Eteplirsen – Completed Gene Therapy Clinical Trials Starting & Completion Year for Duchenne Muscular Dystrophy, January’2020

 

Figure 9-1: Gene Therapy for Retinal Dystrophy Disorder

Figure 9-2: Global - Estimated Cases of Retinal Dystrophy (Million), January’2020

Figure 9-3: Total Genes Responsible for Causing Retinal Disorders

Figure 9-4: Completed Gene Therapy Clinical Trials for Retinal Dystrophy - Starting & Completion Year, January’2020

 

Figure 10-1: UK – Total Population with Heart Disease (Million), 2019

Figure 10-2: Global - Status of Gene Therapy Clinical Trials Conducted for Cardiovascular Diseases, January’2020

Figure 10-3: Global - Status of Gene Therapy Clinical Trials Conducted for Cardiovascular Diseases (%), January’2020

Figure 10-4: Therapeutic Genes for Cardiovascular Disorders Gene Therapy Approach

Figure 10-5: Global - Clinical Trials for Cardiovascular Diseases - Start & Estimated Completion Year, January’ 2020

Figure 10-6: Global - Neovasculgen® – Completed Clinical Trials, January’ 2020

 

Figure 11-1: Global - Cases of Adenosine Deaminase Deficiency (%), January’ 2020

Figure 11-2: Global - Early & Late Onset Adenosine Deaminase Deficiency Deficiency (%), January’ 2020

Figure 11-3: Global - Adenosine Deaminase Deficiency Gene Therapy Clinical Trials Completion Years, 2020

Figure 11-4: Global - Starting & Completion Year of Completed Gene Therapy Clinical Trials for Adenosine Deaminase Deficiency, 2020

Figure 11-5: Global - Strimvelis® – Ongoing Clinical Trial Expected Starting & Completion Year for Adenosine Deaminase Deficiency, January’ 2020

 

Figure 13-1: Timeline of the Approved Gene Therapy Products

 

Figure 14-1: Kymriah – Dose for Acute Lymphoblastic Leukemia for Body Weight Less than 50 kg (CAR-T Cells Million/kg), January’ 2020

Figure 14-2: Kymriah® – Dose for Acute Lymphoblastic Leukemia for Body Weight above 50kg (CAR-T Cells Million/kg), January’ 2020

Figure 14-3: Kymriah® – Dose for Refractory or Relapsed Lymphoblastic Leukemia (CAR-T Cells Million/kg), January’ 2020

Figure 14-4: Kymriah® – Half Yearly Sales (US$ Million), 2018

Figure 14-5: Global – Kymriah® Quarterly Sales (US$ Million), Q1- Q3, 2019

Figure 14-6: Global – Kymriah® Sales (US$ Million), Q1 – Q3, 2018 & 2019

Figure 14-7: Kymriah® – Initial Approval Year by US FDA & EMA

Figure 14-8: Yescarta® – Dose Strength for Lymphoma (CAR-T Cells Million/kg), January’ 2020

Figure 14-9: Global – Yescarta® Annual Sales (US$ Million), 2017 & 2018

Figure 14-10: Global – Yescarta® Quarterly Sales (US$ Million), Q1 – Q4, 2018

Figure 14-11: Regional – Yescarta® Quarterly Sales (US$ Million), Q4, 2018

Figure 14-12: Global – Yescarta® Quarterly Sales (US$ Million), Q1 – Q3, 2019

Figure 14-13: Yescarta® – Initial US FDA & EMA Approval Year

Figure 14-14: Spinraza® – Treatment Course with the Required Dosage (mg/day), January’ 2020

Figure 14-15: Spinraza® – Price of 5 ml Vial & Price/ml Solution (US$), January’ 2020

Figure 14-16: Spinraza® – Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January’ 2020

Figure 14-17: Global – Spinraza® Quarterly Sales (US$ Million), Q1 – Q4, 2018

Figure 14-18: Global – Spinraza® Quarterly Sales (US$ Million), Q1 – Q4, 2018 & 2019

Figure 14-19: Spinraza – Annual Sales – US v/s Row (US$ Million), 2018

Figure 14-20: Spinraza – Annual Sales – US v/s Row (%), 2018

Figure 14-21: Spinraza® – Initial US FDA & EMA Approval Year

Figure 14-22: Zolgensma® – Concentration of Vector Genome per ml Available in the Kit of 5.5 & 8.3 ml (Trillion), January’ 2020

Figure 14-23: Zolgensma – Available Dosing Pattern (Volume) per Body Weight of the Patient, January’ 2020

Figure 14-24: Annual Treatment Cost - Zolgensma v/s Other Therapy (US$ Million), 2019

Figure 14-25: Zolgensma – Initial US FDA & EMA Approval Year

Figure 14-26: Luxturna – Recommended Dose of the Drug (Vector Genomes Million), January’ 2020

Figure 14-27: Luxturna – Dose Concentrations (Vector Genomes Million), January’ 2020

Figure 14-28: Luxturna – Treatment Price for Single & Both Eyes (US$ Million), January’ 2020

Figure 14-29: Global – Luxturna Quarterly Sales (US$ Million), Q1 – Q4, 2018

Figure 14-30: Global – Luxturna Quarterly Sales (US$ Million), Q1, 2018 & 2019

Figure 14-31: Global – Luxturna Quarterly Sales (US$ Million), Q2, 2018 & 2019

Figure 14-32: Global – Luxturna External Research & Development Expenses (US$ Million), Q1, 2018 & 2019

Figure 14-33: Global – Luxturna External Research & Development Expenses (US$ Million), Q2, 2018 & 2019

Figure 14-34: Luxturna – Initial US FDA & EMA Approval Year

Figure 14-35: Strimvelis – Minimum & Maximum Concentration (CD34+ Million Cells/ml), 2020

Figure 14-36: Strimvelis – Recommended Dose (CD34+ Million Cells/kg), 2020

Figure 14-37: Strimvelis – Research & Development Expenses (US$ Million), 2017 & 2018

Figure 14-38: Strimvelis – Selling, General & Administrative Expenses (US$ Million), 2017 & 2018

Figure 14-39: Strimvelis – Research & Development Expenses (US$ Million), Q3, 2018 - 2019

Figure 14-40: Strimvelis – Selling, General & Administrative Expenses (US$ Million), Q3, 2018 & 2019

Figure 14-41: Strimvelis – EMA Issue & Expiry Year

Figure 14-42: Eteplirsen – Average Recommended Dose of the Drug (mg/kg), January’ 2020

Figure 14-43: Eteplirsen – Price of Intravenous Solution (US$), January’ 2020

Figure 14-44: Eteplirsen – Cost of Treatment (US$), 2016

Figure 14-45: Global – Eteplirsen Quarterly Sale (US$ Million), Q1 – Q4, 2018

Figure 14-46: Global – Eteplirsen Quarterly Sales (US$ Million), Q2 – Q3, 2018 & 2019

Figure 14-47: Imlygic – Recommended Dose & Schedule for Treatment (pfu/ml), January’ 2020

Figure 14-48: Imlygic – Price of Drug Injectable Suspension 1mpfu/ml (US$), January’ 2020

Figure 14-49: Imlygic – Price of Drug Injectable Suspension 100 mpfu/ml (US$), January’ 2020

Figure 14-50: Global – Imlygic Expected Total Sale (US$ Million), 2016 & 2022

 

Figure 15-1: Global - Gene Therapy Clinical Trials by Phase (Number),2020 till 2026

Figure 15-2: Global - Gene Therapy Clinical Trials by Country (Number),2020 till 2026

Figure 15-3: Global - Gene Therapy Clinical Trials by Formulation (Number),2020 till 2026

Figure 15-4: Global - Gene Therapy Clinical Trials by Company (Number),2020 till 2026

Figure 15-5: Global - Gene Therapy Clinical Trials by Target (Number),2020 till 2026

Figure 15-6: Global - Gene Therapy Clinical Trials by Indication (Number),2020 till 2026

 

Figure 18-1: Factors Leading to Significant Growth of Gene Therapy Market

Figure 18-2: Global - Expected Gene Therapy Market Size (US$ Million), 2018 - 2026

Figure 18-3: India – Patients with Diseases Treated by Gene Therapy, 2019

Figure 18-4: India – Patients with Diseases Treated by Gene Therapy (%), 2019

Figure 18-5: India – Minimum & Maximum Number of People with Rare Diseases, 2019

Figure 18-6: India – Minimum & Maximum Number of People with Rare Diseases (%), 2019

Figure 18-7: Korea – Total Number of New Cancer Cases & Cancer Deaths, 2019

Figure 18-8: Korea – Total Number of New Cancer Cases & Cancer Deaths, 2019

Figure 18-9: Korea – Number of Cancer Deaths v/s Total Population, 2019

Figure 20-1: Predicted Future of Gene Therapy